Protocol proposal for the histological report of the primary tumor in patients with cutaneous melanoma from the task force for cutaneous melanoma of the Valencian Community;Propuesta de protocolo para el informe histológico del tumor primario de los pacientes con un melanoma cutáneo del Grupo de Trabajo para el Melanoma Cutáneo de la Comunidad Valenciana

Actas Dermo-Sifiliograficas

Volumn 98, Issue 7, 2007, Pages 459-465

  Nagore, Eduardo ^a   Monteagudo, C ^b   Pinazo, M I ^b   Botella Estrada, R ^a   Oliver, V ^c   Banuls J ^d   Moragon M ^e   Valcuende, F ^f   Calatrava, A ^a   Mayol Belda, M J ^e   Lazaro R ^f   Niveiro, M ^d   Guillen C ^a  

^a INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^e HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^f HOSPITAL DE LA PLANA   (Spain)

Author keywords

Histology; Melanoma; Protocol

Indexed keywords

CANCER PATIENT; CLINICAL PROTOCOL; CONFERENCE PAPER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MELANOMA; PROGNOSIS; SKIN CANCER; TISSUE SECTION;

CLINICAL PROTOCOLS; FORMS AND RECORDS CONTROL; HISTOLOGICAL TECHNIQUES; HUMANS; MEDICAL RECORDS; MELANOMA; NEOPLASM INVASIVENESS; PROGNOSIS; SKIN NEOPLASMS;

EID: 34548418529     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/S1578-2190(07)70488-2     Document Type: Conference Paper

References (53)

1. Clark WH Jr., From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969;29:705-27.
2. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;172:902-8.
3. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622-34.
4. Vollmer RT. Malignant melanoma. Amultivariate analysis of prognostic factors. Pathol Annu. 1989;24 Pt 1:383-407.
5. Azzola MF, Shaw HM, Thompson JF, Soong SJ, Scolyer RA, Watson GF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3,661 patients from a single center. Cancer. 2003;97:1488-98.
6. Worth AJ, Gallagher RP, Elwood JM, Yang PC, Lamb C, Spinelli JJ, et al. Pathologic prognostic factors for cutaneous malignant melanoma: the Western Canada Melanoma Study. Int J Cancer. 1989;43:370-5.
7. Barnhill RL, Fine JA, Roush GC, Berwick M. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer. 1996;78:427-32.
8. Ostmeier H, Fuchs B, Otto F, Mawick R, Lippold A, Krieg V, et al. Can immunohistochemical markers and mitotic rate improve prognostic precision in patients with primary melanoma? Cancer. 1999;85:2391-9.
9. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-48.
10. Thorn M, Ponten F, Bergstrom R, Sparen P, Adami HO. Clinical and histopathologic predictors of survival in patients with malignant melanoma: a population-based study in Sweden. J Natl Cancer Inst. 1994;86:761-9.
11. Masback A, Olsson H, Westerdahl J, Ingvar C, Jonsson N. Prognostic factors in invasive cutaneous malignant melanoma: a population-based study and review. Melanoma Res. 2001;11:435-45.
12. Averbook BJ, Fu P, Rao JS, Mansour EG. A long-term analysis of 1,018 patients with melanoma by classic Cox regression and tree-structured survival analysis at a major referral center: Implications on the future of cancer staging. Surgery. 2002;132:589-602; discussion 602-4.
13. Levi F, Randimbison L, La Vecchia C, Te VC, Franceschi S. Prognostic factors for cutaneous malignant melanoma in Vaud, Switzerland. Int J Cancer. 1998;78:315-9.
14. MacKie RM, Aitchison T, Sirel JM, McLaren K, Watt DC. Prognostic models for subgroups of melanoma patients from the Scottish Melanoma Group database 1979-86, and their subsequent validation. Br J Cancer. 1995;71:173-6.
15. Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA. A multifactorial analysis of melanoma. II. Prognostic factors in patients with stage I (localized) melanoma. Surgery. 1979; 86:343-51.
16. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg. 1995;181:193-201.
17. Blois MS, Sagebiel RW, Abarbanel RM, Caldwell TM, Tuttle MS. Malignant melanoma of the skin. I. The association of tumor depth and type, and patient sex, age, and site with survival. Cancer. 1983;52:1330-41.
18. Clemente CG, Mihm MC Jr., Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996;77:1303-10.
19. Day CL Jr, Harrist TJ, Gorstein F, Sober AJ, Lew RA, Friedman RJ, et al. Malignant melanoma. Prognostic significance of «microscopic satellites» in the reticular dermis and subcutaneous fat. Ann Surg. 1981;194:108-12.
20. Drzewiecki KT, Frydman H, Andersen K, Poulsen H, Ladefoged C, Vibe P. Malignant melanoma. Changing trends in factors influencing metastasis-free survival from 1964 to 1982. Cancer. 1990;65:362-6.
21. Elder D. Tumor progression, early diagnosis and prognosis of melanoma. Acta Oncol. 1999;38:535-47.
22. Francken AB, Shaw HM, Thompson JF, Soong SJ, Accortt NA, Azzola MF, et al. The prognostic importance of tumor mitotic rate confirmed in 1,317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol. 2004; 11:426-33.
23. Guerry DT, Synnestvedt M, Elder DE, Schultz D. Lessons from tumor progression: the invasive radial growth phase of melanoma is common, incapable of metastasis, and indolent. J Invest Dermatol. 1993;100:342S-5S.
24. Harrist TJ, Rigel DS, Day CL Jr., Sober AJ, Lew RA, Rhodes AR, et al. «Microscopic satellites» are more highly associated with regional lymph node metastases than is primary melanoma thickness. Cancer. 1984;53:2183-7.
25. Hsueh EC, Lucci A, Qi K, Morton DL. Survival of patients with melanoma of the lower extremity decreases with distance from the trunk. Cancer. 1999;85:383-8.
26. Kashani-Sabet M, Sagebiel RW, Ferreira CM, Nosrati M, Miller JR, 3rd. Vascular involvement in the prognosis of primary cutaneous melanoma. Arch Dermatol. 2001;137: 1169-73.
27. Kesmodel SB, Karakousis GC, Botbyl JD, Canter RJ, Lewis RT, Wahl PM. et al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol. 2005;12:449-58.
28. Leon P, Daly JM, Synnestvedt M, Schultz DJ, Elder DE, Clark WH Jr. The prognostic implications of microscopic satellites in patients with clinical stage I melanoma. Arch Surg. 1991;126:1461-8.
29. McGovern VJ, Shaw HM, Milton GW, Farago GA. Lymphocytic infiltration and survival in malignant melanoma. En: Ackerman AB, editor. Pathology of malignant melanoma. New York: Masson Publishing; 1981. p. 341.
30. McGovern VJ, Shaw HM, Milton GW. Prognosis in patients with thin malignant melanoma: influence of regression. Histopathology. 1983;7:673-80.
31. Schmoeckel C, Bockelbrink A, Bockelbrink H, Koutsis J, Braun-Falco O. Low- and high-risk malignant melanoma-I. Evaluation of clinical and histological prognosticators in 585 cases. Eur J Cancer Clin Oncol. 1983;19:227-35.
32. Stadelmann WK, Rapaport DP, Soong SJ, Reintgen DS, Buzaid AC, Balch CM. Prognostic clinical and pathologic features. En: Balch CM, Houghton A Jr., Sober AJ, Soong SJ, editors. Cutaneous melanoma. St. Louis, MO: Quality Medical Publishing, Inc; 1998. p. 11-36.
33. Vossaert KA, Silverman MK, Kopf AW, Bart RS, Rigel DS, Friedman RJ, et al. Influence of gender on survival in patients with stage I malignant melanoma. J Am Acad Dermatol. 1992;26:429-40.
34. Nagore E, Oliver V, Botella-Estrada R, Moreno-Picot S, Insa A, Fortea JM. Prognostic factors in localized invasive cutaneous melanoma: high value of mitotic rate, vascular invasion and microscopic satellitosis. Melanoma Res. 2005;15: 169-77.
35. Nagore Enguidanos E, Oliver Martínez V, Botella Estrada R, Insa Molla A, Fortea Baixauli JM. Factores pronósticos en el melanoma maligno cutáneo localizado: estudio de 639 pacientes. Med Clin (Barc). 2005;124:361-7.
36. Scolyer RA, Shaw HM, Thompson JF, Li LX, Colman MH, Lo SK, et al. Interobserver reproducibility of histopathologic prognostic variables in primary cutaneous melanomas. Am J Surg Pathol. 2003;27:1571-6.
37. Heenan PJ, Matz LR, Blackwell JB, Kelsall GR, Singh A, Ten Seldam RE, et al. Inter-observer variation between pathologists in the classification of cutaneous malignant melanoma in western Australia. Histopathology. 1984;8: 717-29.
38. Crowson AN, Magro CM, Mihm MC. Prognosticators of melanoma, the melanoma report, and the sentinel lymph node. Mod Pathol. 2006;19 Suppl 2:S71-87.
39. Barnhill RL, Mihm MC Jr. Histopathology and precursor lesions. En: Balch CM, Houghton AN, Sober A, Soong SJ, editors. Cutaneous melanoma. St. Louis, MO: Quality Medical Publishing, Inc; 1998. p. 103-33.
40. McGovern VJ, Cochran AJ, Van der Esch EP, Little JH, MacLennan R. The classification of malignant melanoma, its histological reporting and registration: a revision of the 1972 Sydney classification. Pathology. 1986;18:12-21.
41. McCarthy SW, Crotty KA, Scolyer RA. Desmoplastic melanoma and desmoplastic neurotropic melanoma. En: LeBoit PE, Burg G, Weedon D, Sarasin A, editors. Pathology and genetics of skin tumours. Lyon: IARC Press; 2006. p. 76-8.
42. Barnhill RL, Katzen J, Spatz A, Fine J, Berwick M. The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma. J Cutan Pathol. 2005;32:268-73.
43. McDermott NC, Hayes DP, al-Sader MH, Hogan JM, Walsh CB, Kay EW, et al. Identification of vertical growth phase in malignant melanoma. A study of interobserver agreement. Am J Clin Pathol. 1998;110:753-7.
44. Swetter SM, Ecker PM, Johnson DL, Harvell JD. Primary dermal melanoma: a distinct subtype of melanoma. Arch Dermatol. 2004;140:99-103.
45. Day CL Jr., Mihm MC Jr., Lew RA, Harris MN, Kopf AW, Fitzpatrick TB, et al. Prognostic factors for patients with clinical stage I melanoma of intermediate thickness (1.51 - 3.39 mm). A conceptual model for tumor growth and metastasis. Ann Surg. 1982;195:35-43.
46. Guitart J, Lowe L, Piepkorn M, Prieto VG, Rabkin MS, Ronan SG, et al. Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch Dermatol. 2002;138:603-8.
47. Ronan SG, Eng AM, Briele HA, Shioura NN, Das Gupta TK. Thin malignant melanomas with regression and metastases. Arch Dermatol. 1987;123:1326-30.
48. Sondergaard K, Hou-Jensen K. Partial regression in thin primary cutaneous malignant melanomas clinical stage I. A study of 486 cases. Virchows Arch A Pathol Anat Histopathol. 1985;408:241-7.
49. Mascaró JM, Molgo M, Castel T, Castro J. Plasma cells within the infiltrate of primary cutaneous malignant melanoma of the skin. A confirmation of its histoprognostic value. Am J Dermatopathol. 1987;9:497-9.
50. Kelly JW, Sagebiel RW, Calderon W, Murillo L, Dakin RL, Blois MS. The frequency of local recurrence and microsatellites as a guide to reexcision margins for cutaneous malignant melanoma. Ann Surg. 1984;200:759-63.
51. Shaikh L, Sagebiel RW, Ferreira CM, Nosrati M, Miller JR 3rd, Kashani-Sabet M. The role of microsatellites as a prognostic factor in primary malignant melanoma. Arch Dermatol. 2005;141:739-42.
52. Friedman RJ, Rigel DS, Kopf AW, Lieblich L, Lew R, Harris MN, et al. Favorable prognosis for malignant melanomas associated with acquired melanocytic nevi. Arch Dermatol. 1983;119:455-62.
53. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135-47.